Sumitomo Mitsui Trust Group Inc. Sells 19,090 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 6.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 269,369 shares of the company’s stock after selling 19,090 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.39% of COMPASS Pathways worth $1,697,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Logos Global Management LP lifted its holdings in shares of COMPASS Pathways by 349.3% during the 2nd quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock worth $7,001,000 after acquiring an additional 901,050 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of COMPASS Pathways by 1,518.4% during the 2nd quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock worth $1,593,000 after acquiring an additional 247,500 shares during the period. Hennion & Walsh Asset Management Inc. bought a new position in shares of COMPASS Pathways during the 2nd quarter worth about $664,000. Tidal Investments LLC lifted its holdings in shares of COMPASS Pathways by 43.6% during the 1st quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after acquiring an additional 5,795 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of COMPASS Pathways during the 1st quarter worth about $201,000. 46.19% of the stock is owned by institutional investors.

Insider Transactions at COMPASS Pathways

In other news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of COMPASS Pathways stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the completion of the sale, the insider now owns 6,905,774 shares in the company, valued at $41,779,932.70. The trade was a 27.81 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.25% of the stock is owned by corporate insiders.

COMPASS Pathways Trading Up 2.1 %

CMPS opened at $4.76 on Wednesday. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $325.68 million, a PE ratio of -2.16 and a beta of 2.29. COMPASS Pathways plc has a 1-year low of $4.05 and a 1-year high of $12.75. The firm has a 50-day moving average price of $6.05 and a two-hundred day moving average price of $6.76.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same quarter last year, the firm posted ($0.67) earnings per share. As a group, equities analysts anticipate that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. HC Wainwright cut their price target on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a report on Friday, November 1st. Royal Bank of Canada cut their price target on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Maxim Group cut their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Canaccord Genuity Group cut their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $30.67.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.